株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中国のソラフェニブ市場の分析

Investigation Report on Chinese Sorafenib Market, 2018-2022

発行 China Research and Intelligence 商品コード 335239
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.52円で換算しております。
Back to Top
中国のソラフェニブ市場の分析 Investigation Report on Chinese Sorafenib Market, 2018-2022
出版日: 2018年07月11日 ページ情報: 英文 30 Pages
概要

当レポートでは、中国のソラフェニブ市場について調査分析し、売上、価格、主要メーカーの分析、市場の見通しなど、体系的な情報を提供しています。

第1章 ソラフェニブの基本概念

  • 適応
  • 中国におけるソラフェニブの発展の歴史
  • 中国におけるソラフェニブの登録情報

第2章 中国におけるソラフェニブの売上

  • 中国におけるソラフェニブの総売上
  • 中国におけるソラフェニブの売上:地域別
  • ソラフェニブの売上:剤形別

第3章 中国におけるソラフェニブ主要メーカーの分析

  • Bayer
  • インドの企業
  • 中国製ジェネリック医薬品の進展

第4章 中国におけるソラフェニブの価格

  • Bayer
  • インドから密輸されたジェネリック医薬品

第5章 中国のソラフェニブ市場の見通し

  • 市場規模の予測
  • 競合パターンの予測
目次
Product Code: 1807304

Sorafenib is mainly used to treat inoperable advanced renal cell carcinoma and inoperable or metastasized primary hepatocellular carcinoma. Sorafenib was jointly developed by Bayer and ONYX. In 2006, the drug was approved to be imported to China. In 2008, it entered China after the liver cancer indication was approved by the CFDA.

Liver cancer is the sixth most common cancer in the world and the second leading cause of cancer-related death. It is estimated that over 800 thousand cases of liver cancer are diagnosed worldwide (more than 400 thousand cases in China) every year with a continuous increase in incidence. In 2012, around 746 thousand people died of liver cancer, including 383 thousand deaths in China. As the most effective targeted drug for liver cancer, Sorafenib brings hope to numerous tumor patients.

According to CRI, Sorafenib has been growing since it entered China. In 2017, its sales value in China was about CNY 195 million. Currently, Sorafenib legally sold in China are all Bayer's products.

According to CRI, cancer incidence continues to rise in China because of aggravating environmental pollution and changing lifestyle. Therefore, there will be a great demand for Sorafenib. After several links of circulation, Bayer's Sorafenib is so high-priced that many low-income patients cannot afford it. Some patients choose to purchase Sorafenib produced by Indian enterprises such as NATCO and smuggled to China because the price is only 2%-3% of that of Bayer's Sorafenib. Some Chinese enterprises has also started the development of generic drugs.

It is possible that China-made Sorafenib will appear on the market after 2022.

Topics Covered:

  • Sales of Sorafenib in China
  • Prices of Sorafenib in China
  • Sales of Sorafenib in China by region
  • Sales of India-made Sorafenib in China
  • Prospects of Chinese Sorafenib market

Table of Contents

1 Basic Concepts of Sorafenib

  • 1.1 Indications
  • 1.2 Development History of Sorafenib in China
  • 1.3 Registration Information of Sorafenib in China

2 Sales of Sorafenib in China, 2013-2017

  • 2.1 Overall Sales of Sorafenib in China
    • 2.1.1 Sales Value
    • 2.1.2 Sales Volume
  • 2.2 Sales of Sorafenib in China by Region
    • 2.2.1 Sales Value by Region
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Sorafenib by Dosage Form

3 Analysis on Major Sorafenib Manufacturers in China

  • 3.1 Bayer
  • 3.2 Indian Enterprises
  • 3.3 Progress of China-made Generic Drugs

4 Prices of Sorafenib in China, 2017-2018

  • 4.1 Bayer (Product Trade Name: NATCO)
  • 4.2 Generic Drugs Smuggled from India

5 Prospects of Chinese Sorafenib Market, 2018-2022

  • 5.1 Forecast on Market Size
  • 5.2 Forecast on Competition Pattern

Selected Charts

  • Chart Governmental Approval of Sorafenib in China
  • Chart Sales Value of Sorafenib Legally Sold in China, 2013-2017
  • Chart Sales Value of Sorafenib in Parts of China, 2013-2017
  • Chart Sales Volume of Sorafenib in China, 2013- 2017
  • Chart Sales Volume of Sorafenib in Parts of China, 2013-2017
  • Chart Market Share of Sorafenib Manufacturers by Sales Value in China, 2013-2017
  • Chart Market Share of Sorafenib Manufacturers by Sales Volume in China, 2013-2017
  • Chart Sales Value and Market Share of Sorafenib Tablets in China, 2013-2017
  • Chart Sales Volume and Market Share of Sorafenib Tablets in China, 2013-2017
  • Chart Prices of Bayer's Sorafenib in Several Chinese Cities, 2017-2018
Back to Top